CZPCold Zero Power (nuclear power)
CZPCondenser Zone Plate (microscopy)
CZPCataract, Zonular Pulverulent
CZPCentrum Zaopatrzenia Poczty (Polish: Mail Supply Center)
CZPCombat Zone Professionals (gaming)
CZPCiej Zadawane Pytania (Polish: Frequently Asked Questions)
CZPConcept Z Performance (Phoenix, AZ)
References in periodicals archive ?
Evidence that supports the use of CZP in the treatment of RA is derived from three pivotal trials conducted in patients with moderately to severely active RA (nine or more swollen and tender joints).
Three recent studies in RA were presented at EULAR (European League against Rheumatology) and ACR (American College of Rheumatology) in 2007 using CZP, a monotherapy study (2) in comparison to true placebo and two studies using CZP RAPID-I (3,4) and RAPID-II (5) in combination with methotrexate (MTX) in MTX-inadequate responders.
In patients with active RA despite methotrexate treatment, the addition of CZP provides clinical improvements that were sustained over 3 years, inhibits joint damage progression, and was shown to be well tolerated.
Demonstrates an additional 400mg dose of CZP successfully recaptured and maintained remission rates in patients with disease exacerbation who were naive to anti-TNF treatment.
CZP demonstrated sustained efficacy and remission among patients with fistulising CD over 3 years, as measured by Harvey-Bradshaw Index (a symptom severity questionnaire).
To receive a copy of the prospectus for CZP, please contact the Capital Markets Group at the American Stock Exchange at (212) 306-1659.
Ordinary shares of CZP are traded on the Moscow exchange MICEX-RTS under ticker CHZN and Global Depository Receipts (GDR) are traded on the London Stock Exchange under ticker CHZN.
After recent price surge CZP shares are trading at high P/E'12 of 10.
The deal will see Alumasc retaining the freehold on the firm's Walsall Road factory, which it will then lease to CZP.
In contrast, CZP + MTX co-therapy inhibited joint destruction even in patients with these characteristics compared to MTX monotherapy.
In RA patients with longstanding low to moderate disease activity, the addition of CZP to non-biologic DMARDs was well tolerated and associated with increased rates of remission, prevention of disease worsening, and improved work productivity and daily activity.